A Phase 1, Multicentre, Randomised, Double-blind Study to Assess Safety and Tolerability of Repeated Intracerebroventricular Administration of sNN0031 Infusion Solution to Patients With Parkinson's Disease

Trial Profile

A Phase 1, Multicentre, Randomised, Double-blind Study to Assess Safety and Tolerability of Repeated Intracerebroventricular Administration of sNN0031 Infusion Solution to Patients With Parkinson's Disease

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs SNN 0031 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Newron Sweden AB
  • Most Recent Events

    • 26 Jan 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 14 Jan 2015 Status changed from planning to recruiting, according to a Newron Pharmaceuticals media release.
    • 19 Jun 2013 Regulatory meetings in Europe and the US have been initiated to seek input and agreement on this proposed study, according to a Newron Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top